Pulmocide develops opelconazole, an inhaled dry‑powder azole antifungal that delivers 2–3 µm particles deep into the lungs, achieving lung concentrations >2000‑fold higher than plasma. The formulation provides localized treatment and prophylaxis for invasive pulmonary aspergillosis and other Aspergillus‑related lung diseases while minimizing systemic toxicity and drug‑drug interactions. Opelconazole is in a Phase 3 superiority trial and holds FDA orphan, Fast‑Track and QIDP designations.
Funding
Funding not disclosed
Founders
Product
Problem
Invasive pulmonary aspergillosis and other Aspergillus‑related lung diseases carry a high mortality rate and often fail to respond to standard systemic antifungal therapies. Existing oral or intravenous agents provide limited drug concentrations at the site of infection, expose patients to systemic toxicity, and create significant drug‑drug interaction risks. Consequently, patients with refractory disease or those requiring long‑term prophylaxis have few effective treatment options.
Solution
Pulmocide is advancing opelconazole, a novel inhaled azole antifungal designed to deliver therapeutic drug levels directly to the airways where Aspergillus infection resides. The dry‑powder formulation produces aerosol particles sized 2–3 µm, matching the dimensions of fungal spores and enabling deep lung deposition. Once deposited, opelconazole exhibits >2000‑fold higher concentrations in lung tissue than in plasma, providing potent, localized antifungal activity while minimizing systemic exposure and associated adverse events. The molecule retains activity against multiple pathogenic Aspergillus species and can be co‑administered with standard systemic antifungals, supporting both treatment of refractory invasive disease and prophylaxis in high‑risk populations. Opelconazole is currently in a Phase 3, randomized superiority trial for patients who have not responded adequately to standard‑of‑care therapy and has received orphan‑drug, Fast‑Track, and QIDP designations from the FDA, as well as orphan status in the EU, facilitating accelerated regulatory pathways.
Target Audience
The primary customers are pulmonologists, infectious‑disease physicians, and transplant centers managing invasive pulmonary aspergillosis, chronic Aspergillus‑related lung conditions, and patients requiring antifungal prophylaxis.
Features
- Dry‑powder inhaler delivering particles of 2–3 µm for optimal alveolar penetration.
- Lung retention exceeding 2000 × plasma levels, ensuring high local drug exposure.
- Low systemic bioavailability, reducing systemic toxicity and drug‑drug interaction potential.
- Broad in‑vitro potency against Aspergillus fumigatus, A. terreus, A. flavus, and A. carbonarius.
- Demonstrated efficacy in animal models and compassionate‑use “Specials” program with favorable safety profile.
- Compatibility with concurrent systemic antifungal regimens for combination therapy.
- Supported by FDA orphan, Fast‑Track, and QIDP designations and EU orphan designation, enabling expedited review.